RA Capital β 2015 Investments
6 investments dated 2015 Β· listed companies and verified rows first Β· show all
Freenome develops early-stage cancer detection technology using blood tests to identify cancer in its earliest, most treatable phases.
AI & Machine LearningBiotechDigital HealthHealthtechMedical DevicesLondon
Riley Ennis(Co-Founder and Chief Product Officer)Stuart Lawson(Director)Charles Roberts(Director)Gabriel Otte(Director)
C4 Therapeutics develops small molecule medicines called degraders that use targeted protein degradation (TPD) to eliminate disease-causing proteins via the body's ubiquitin proteasome system.
BiotechCambridge, US
Marc Cohen(Executive Officer, Director)Jason Fisherman(Executive Officer, Director)Miles Stuchin(Director)William M. Scalzulli(Director)Kenneth Anderson(Director)Malcolm S. Salter(Director)
BiotechTucson, US
Jon Faiz Kayyem, Ph.D.(Director)Louis Breton(Executive Officer, Director)David Baltimore, Ph.D.(Director)Harry A. George(Director)Bhavin Raval(Executive Officer)David H. Donabedian, Ph.D.(Director)
Board seatPeter KolchinskyΒ· per SEC Form D
Wakefield, US
BoardJoshua S. Phillips(Executive Officer, Director)Darshana Zaveri(Director)
Board seatPeter KolchinskyΒ· per SEC Form D Β· $3M raise Β· filed Aug 2017
BiotechCambridge, US
Douglas A. Treco(Executive Officer, Director)Edward Mathers(Director)Peter Bisgaard(Director)Jason Lettman(Director)Kerry Black(Executive Officer)Markus Goebel(Director)
Rows marked βSEC filingβ are inferred from directors named on the company's SEC Form D β public regulatory data, not a portfolio list published by the firm.